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Nantes, Franceh; Hôpital Pierre Zodba Quitman, Fort de France, Francei; CHU de Bordeaux, Pôle de Santé Publique, Service d’Information Médicale, Bordeaux, Francej
We studied whether addition of enfuvirtide (ENF) to a background combination antiretroviral therapy (cART) would improve
the CD4 cell count response at week 24 in naive patients with advanced HIV disease. ANRS 130 Apollo is a randomized study,
conducted in naive HIV-1-infected patients, either asymptomatic with CD4 counts of <100/mm3 or stage B/C disease with CD4
counts of <200/mm3. Patients received tenofovir-emtricitabine with lopinavir-ritonavir (LPV/r) or efavirenz and were random-
ized to receive ENF for 24 weeks (ENF arm) or not (control arm). The primary endpoint was the proportion of patients with CD4
counts of >200/mm3 at week 24. A total of 195 patients were randomized: 73% had stage C disease, 78% were male, the mean age
was 44 years, the median CD4 count was 30/mm3, and the median HIV-1 RNA load was 5.4 log10 copies/ml. Eighty-one percent of
patients received LPV/r. One patient was lost to follow-up, and eight discontinued the study (four in each arm). The proportions
of patients with CD4 counts of >200/mm3 at week 24 were 34% and 38% in the ENF and control arms, respectively (P  0.53).
The proportions of patients with HIV-1 RNA loads of <50 copies/ml were 74% and 58% at week 24 in the ENF and control arms,
respectively (P < 0.02), and the proportion reached 79% in both arms at week 48. Twenty (20%) and 12 patients (13%) in the
ENF and control arms, respectively, experienced at least one AIDS event during follow-up (P  0.17). Although inducing a more
rapid virological response, addition of ENF to a standard cART does not improve the immunological outcome in naive HIV-in-
fected patients with severe immunosuppression.
Combination antiretroviral therapy (cART) has substantiallyreduced mortality and morbidity in HIV-1-infected patients
since its introduction in 1996 (1, 2). Even patients who initiate
treatment relatively late in the course of the disease have been
shown to benefit from cART (3, 4). However, mortality and mor-
bidity rates remain high in patients who enter HIV care with se-
vere immunodeficiency (5–8), with most progressions to AIDS or
death occurring in the first 6 months following the initiation of
cART (2, 9). Several studies have shown that the magnitude of the
CD4 cell count response at 6 months is associated with a reduction
in the rate of clinical progression (10–12), including crude mor-
tality (13).
Current recommendations support initiating cART with two
nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz
or a boosted protease inhibitor (PI). Optimization of ART in naive
patients presenting with advanced HIV disease is needed to im-
prove their immunological response and reduce the rate of clinical
progression, especially in the first months following the initiation
of treatment.
The aim of the randomized trial described here was to assess
whether the addition of a fourth antiretroviral drug, namely, en-
fuvirtide, to a standard cART therapy would improve the increase
in CD4 cell count in naive HIV-1-infected patients with advanced
HIV disease.
MATERIALS AND METHODS
Study design. The ANRS 130 Apollo trial was an open-label, randomized,
multicenter, nationwide, French clinical trial of three versus four antiret-
roviral drugs at the initial phase of antiretroviral treatment in severely
immunosuppressed HIV-infected patients. Immunosuppression was de-
fined as a CD4 cell count of 100/mm3 if patients were asymptomatic
or 200/mm3 if patients were stage B or C, according to the 1993 Centers
for Disease Control and Prevention classification. The trial statistician
prepared the randomization list, and the codes were known only to him
and the data services programmers and were unknown to the investigators
and coordinators. Randomized treatment assignment was done using a
central computer following the generated list, after eligibility criteria had
been checked centrally at the clinical trials unit.
Patients from 38 HIV clinics in France were eligible if they met the
following inclusion criteria: men or women aged 18 years old; HIV-1
infected, as assessed by a positive Western blot assay result; and naive for
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any ART with a CD4 cell count of 100/mm3 if they were asymptomatic
or 200/mm3 if they had a past or present history of stage B or C disease,
whatever the plasma HIV-1 RNA value. Patients were not eligible if
they had HIV-2 infection or a cancer requiring radio- or chemotherapy, if
they had received any immunomodulator therapy or HIV vaccine, or
if they were pregnant, breast-feeding, or of childbearing age without ef-
fective contraception. Other exclusion criteria included creatinine clear-
ance level of 60 ml/min, hemoglobin level of 8 g/dl, absolute neutro-
phil count of 750/mm3, platelet count of 50,000/mm3, and alkaline
phosphatase or transaminases level 3 times the upper limit of the nor-
mal range (ULN). Patients with chronic hepatitis B or C were eligible if
they did not have cirrhosis with a Child-Pugh score of B or C.
Written informed consent was obtained from all patients. The proto-
col was reviewed and approved by an ethics committee (Comité de Pro-
tection des Personnes) and competent health authority (Agence Française
de Sécurité Sanitaire des Produits de Santé). The trial was conducted in
accordance with the Declaration of Helsinki.
Study treatment regimens. All patients received a standard therapy of
emtricitabine (FTC) coformulated with tenofovir disoproxil fumarate
(Truvada; Gilead) combined with either lopinavir-ritonavir (400/100 mg;
Kaletra; Abbott) twice daily or efavirenz (600 mg; Sustiva; Bristol-Myers
Squibb) once daily, as per the choice of the local investigator. Standard
therapy was defined before randomization.
Patients were centrally randomized (1:1) to receive either a standard
therapy alone (control arm) or an intensified therapy through the addi-
tion of enfuvirtide (Fuzeon; Roche) at 90 mg subcutaneously twice daily
to the standard therapy (enfuvirtide intensification arm). The duration
of the enfuvirtide therapy in the intensification group was 24 weeks. All
subjects were followed for 48 weeks. Randomization was stratified by
clinical center, backbone therapy (efavirenz or boosted lopinavir), and
clinical stage of HIV infection (stage C yes or no). If a patient had had a
recent infection, no minimal delay between infection and initiation of
ART was required.
Changes in the standard therapy were permitted throughout the du-
ration of the study to control for the toxic effects of antiretroviral drugs,
provided that patients continued to receive a combination of two nucleo-
sides with either efavirenz or a boosted protease inhibitor. All patients
received prophylaxis for Pneumocystis jirovecii pneumonia and toxoplas-
mosis until their CD4 cell count increased, per current guidelines (14).
Outcome measures. The primary endpoint was the proportion of pa-
tients with a CD4 cell count of 200/mm3 at week 24. We chose an
immunological endpoint since the CD4 response is associated with a re-
duction in clinical progression, which was our main goal in this popula-
tion of patients with advanced HIV disease. Secondary endpoints in-
cluded the proportion of patients who reached plasma HIV-1 viral loads
of 50 copies/ml at weeks 12, 24, and 48; the proportion of patients with
a CD4 cell count of 200/mm3 at week 48; the changes in CD4 cell count
and plasma HIV-1 RNA levels between baseline and week 48; drug toler-
ability; the incidence of clinical HIV- and non-HIV-related events, death,
and immune reconstitution and inflammatory syndrome (IRIS) reac-
tions; and the proportion of patients who interrupted the therapeutic
strategy allocated by randomization. Therapeutic strategy interruptions
were defined as (i) interruption of enfuvirtide for more than 1 month in
the intensification arm, (ii) addition of enfuvirtide in the control arm, or
(iii) changes in the backbone therapy leading to administration of a com-
bination other than two nucleosides and a boosted PI or two nucleosides
and efavirenz.
Local laboratories assessed HIV-1 RNA levels and CD4 cell counts at
screening, at enrollment, and at weeks 2, 4, 8, 12, 24, 36, and 48. An
independent data and safety monitoring board regularly reviewed avail-
able safety and efficacy data. The severity of clinical and laboratory abnor-
malities was graded according to the ANRS scale for grading the severity of
adverse events in adults. Investigators evaluated the association between
the study regimen and each adverse event. Results of additional secondary
endpoints (change in drug susceptibility and HIV-1 tropism) will be re-
ported elsewhere.
IRIS case definition. IRIS was defined as evidence of symptoms tem-
porally related to the initiation of cART with an increase in CD4 cell
counts and/or a decrease in plasma HIV-1 RNA levels, consistent with an
inflammatory condition, that could not be explained by a newly acquired
FIG 1 ANRS 130 Apollo trial profile.
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infection, the failure of treatment of a previously diagnosed infection, or
side effects of cART itself (15). All cases of IRIS required review by an
event review board.
Statistical analysis. We assumed that in the control arm, 30% of sub-
jects would reach the primary efficacy endpoint. Thus, a sample size of 103
patients in each arm was necessary to provide at least 80% power, with an
alpha risk of 5%, to detect a proportion of 50% of patients reaching the
primary endpoint in the enfuvirtide arm. Primary efficacy analyses were
conducted on an intent-to-treat basis. They included all enrolled patients,
regardless of whether they received at least one dose of the study medica-
tion or whether they completed their allocated treatment. When CD4 cell
count values were missing, they were considered treatment failures (i.e.,
CD4 count, 200/mm3) in the primary efficacy analyses. Changes in CD4
cell count and HIV-1 RNA level were calculated on the basis of the avail-
able data. Differences were assessed using the chi-square test for compar-
ing proportions and the Mann-Whitney/Wilcoxon test for comparing
medians. In all analyses, the baseline was defined as the week 0 visit date.
In the case of discontinuation of the trial, data were included up to the last
visit date.
All statistical analyses were performed with SAS, version 9.1.3, service
pack 2, software (SAS Institute).
RESULTS
Patient disposition and baseline characteristics. From March
2006 to December 2008, 208 patients were screened and 195 pa-
tients were randomized. Among the 13 patients who were not
randomized into the study, 5 had a CD4 cell count of 200 cells/
mm3 at baseline. Other reasons are described in the trial profile
(Fig. 1). One hundred one patients were randomized in the
enfuvirtide group and 94 were randomized in the control one.
One patient was not affiliated with the French social security sys-
tem and had to be excluded from the analysis. One patient was lost
to follow-up, eight patients (four in each arm) discontinued the
study, including five who discontinued before week 0 (mostly be-
cause of patient demotivation) and did not receive study medica-
tion.
Patient baseline characteristics were well-balanced across the
arms (Table 1). Patients were primarily men (78%), and the mean
age was 44 years. Most patients (82%) presented with a late HIV
diagnosis (delay between diagnosis and study entry, less than 6
months). The baseline median CD4 cell count was 30/mm3; 66%
of the patients entered the study with a CD4 cell count of 50
cells/mm3. The baseline plasma HIV-1 RNA level was 5.4 log10
copies/ml. Lopinavir-ritonavir was prescribed to 81% of patients,
and efavirenz was prescribed to 19%. Most patients were stage C
(73%), and 108 patients (56%) had an active AIDS event at base-
line. Twenty-nine out of these 108 patients entered the study with
multiple active AIDS events. The most common opportunistic
infections were Pneumocystis jirovecii pneumonia (45 patients)
and toxoplasmosis (16 patients).
Therapeutic strategy interruptions. Therapeutic strategy in-
terruptions occurred in 20 patients, 16 in the intensification arm
(15.8%) and 4 in the control arm (4.3%). In the intensification
arm, 15 patients interrupted enfuvirtide (mostly definitely and
due to poor convenience or local discomfort), and 1 patient
switched from lopinavir to raltegravir because of diarrhea. In the
control arm, one patient received enfuvirtide and raltegravir due
to primary viral resistance at baseline, and three patients simulta-
TABLE 1 Baseline characteristics of the patients in the ANRS 130 Apollo trial
Characteristic
Enfuvirtide group
(n  100)
Control group
(n  94) Total (n  194)
No. (%) male 74 (74) 77 (82) 151 (78)
Mean (SD) age (yr) 44 (9) 43 (10) 44 (10)
No. (%) of patients by mode of infection
Heterosexual contact 55 (55) 51 (54) 106 (55)
Men having sex with men 33 (33) 30 (32) 63 (32)
Injecting drug user 2 (2) 1 (1) 3 (2)
Transfusion 0 (0) 1 (1) 1 (1)
Unknown 10 (10) 11 (12) 21 (11)
No. (%) of patients by clinical stage
A 10 (10) 11 (12) 21 (11)
B 16 (16) 16 (17) 32 (16)
C 74 (74) 67 (71) 141 (73)
No. (%) of patients with active AIDS event at wk 0 55 (55) 53 (56) 108 (56)
No. (%) of patients with delay from HIV diagnosis to wk 0 of 6 mo 84 (84) 75 (80) 159 (82)
Baseline CD4 count (no. of cell/mm3)
Mean (SD) 49 (50) 54 (62) 51 (56)
Median (IQR) 35 (14, 69) 29 (11, 88) 30 (12, 72)
Baseline HIV-1 RNA load (log10 no. of copies/ml)
Mean (SD) 5.3 (0.6) 5.4 (0.6) 5.4 (0.6)
Median (IQR) 5.4 (5–5.8) 5.4 (5–5.8) 5.4 (5–5.8)
No. (%) of patients receiving standard treatment of:
Lopinavir-ritonavir 78 (78) 79 (84) 157 (81)
Efavirenz 22 (22) 15 (16) 37 (19)
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neously received a nonnucleoside reverse transcriptase inhibitor
and a PI with an NRTI because of a poor virologic response; these
were combined with raltegravir in one patient or with enfuvirtide
in another patient.
CD4 cell count and HIV-1 RNA responses. The proportions
of patients with a CD4 cell count of 200/mm3 at week 24 were
38% in the control arm and 34% in the intensification arm (P 
0.53). Applying an extreme case analysis to the missing CD4 values
at week 24 (six in the control arm and five in the intensification
arm) did not change the direction of the result. The median in-
crease in CD4 count at week 24 was 113 cells/mm3 (interquartile
ratio [IQR], 70, 171 cells/mm3) in the enfuvirtide arm versus 129
cells/mm3 (IQR, 76, 194 cells/mm3) in the control arm (P  0.35).
The median CD4 cell count at week 24 was 145 cells/mm3 (IQR,
103, 242 cells/mm3) in the enfuvirtide arm versus 175 cells/mm3
(IQR, 116, 268 cells/mm3) in the control arm (P  0.19). CD4
trends from week 0 to week 48 according to randomization are
depicted in Fig. 2. The lack of difference between the two arms
persisted when considering different subgroups of patients ac-
cording to their absolute CD4 cell count at baseline, i.e., 50,
50, and 100 or 100 cells/mm3.
The proportion of patients with HIV-1 RNA loads of 50 cop-
ies/ml is depicted in Fig. 3. At week 12, 45 patients (46%; 95%
confidence interval [CI], 37 to 56%) in the enfuvirtide arm and 30
patients (33%; 95% CI, 24 to 43%) in the control arm had a
plasma HIV-1 RNA load of 50 copies/ml (P  0.07). At week 24,
70 patients (74%; 95% CI, 65 to 83%) in the enfuvirtide arm and
51 patients (58%; 95% CI, 48 to 68%) in the control arm had a
plasma HIV-1 RNA load of 50 copies/ml (P  0.02). Finally,
similar proportions of patients in both arms reached HIV-1 RNA
loads of 50 copies/ml at week 48 (79% [95% CI, 71 to 88%] in
both arms). A lack of an early virological response, defined as a
decrease in the HIV-1 RNA measure of less than 2 log10 copies/ml
at week 4, was reported in 12 patients (12%) and 16 patients (17%)
in the enfuvirtide arm and in the control arm, respectively (P 
0.31).
Clinical progression and adverse events. Clinical adverse
events reported throughout the duration of the study are shown in
Table 2. There was no difference between arms in the percentage
of patients reporting at least one clinical adverse event, a grade 3 or
4 clinical event, a serious event, or a study treatment-related event.
Enfuvirtide toxicity was limited to nodular or local inflammatory
reactions, mostly grade 1 and 2, reported by 38 patients. Twenty
patients (20%) and 12 patients (13%) in the enfuvirtide arm and
in the control arm, respectively, experienced at least one AIDS
event during follow-up (P  0.17). AIDS events are depicted in
Table 3. Of note, two-thirds of these events were new AIDS-defin-
ing diseases. Four deaths occurred, two in the intensification arm
and two in the control arm. Three out of the four deaths were
related to severe bacterial infections.
An IRIS event was reported in 15 patients (15%) and 20 pa-
tients (21%) in the enfuvirtide arm and in the control arm, respec-
tively (P  0.26). The most frequent manifestations were myco-
bacterial infections (16 cases), folliculitis (9 cases), and
nonrecurrent varicella-zoster (6 cases). The probability of devel-
FIG 2 Median CD4 cell count from week 0 to week 48, ANRS 130 Apollo trial
(ENF, enfuvirtide; data points are medians, and errors bars are omitted for
clarity).
FIG 3 Proportion of patients with HIV-1 RNA loads of 50 copies/ml, ANRS
130 Apollo trial (ENF, enfuvirtide; data points are medians, and errors bars are
omitted for clarity).
TABLE 2 Clinical adverse events in the ANRS 130 Apollo trial
Adverse event
No. (%) of patients
Enfuvirtide
group
(n  100)
Control
group
(n  94)
Total
(n  194)
Clinical adverse events
Any grade 92 (92) 85 (90) 177 (91)
Any grade and trial treatment
related
61 (61) 52 (55) 113 (58)
Grades 3 and 4 23 (23) 28 (30) 51 (26)
Grades 3 and 4 and trial
treatment related
7 (7) 8 (9) 15 (8)
Serious 28 (28) 27 (29) 55 (28)
Serious and study treatment
related
9 (9) 13 (14) 22 (11)
AIDS events 20 (20) 12 (13) 32 (16)
IRIS 15 (15) 20 (21) 35 (18)
Deaths 2 (2) 2 (2) 4 (2)
ANRS 130 Apollo Trial
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oping an IRIS event was not different between the two arms (P 
0.18).
Grade 3 or 4 laboratory abnormalities were found in 21% of
patients, with no difference between arms (P  0.45) (Table 4).
Among 57 grade 3 or 4 laboratory abnormalities, only 7 were
considered by the investigator to be related to study drugs (mostly
hypophosphatemia, hypertriglyceridemia, or proteinuria related
to emtricitabine-tenofovir) (Table 5).
DISCUSSION
Even in Western countries, late diagnosis of HIV infection is fre-
quent. In a British cohort of patients diagnosed with HIV-1 infec-
tion between 1996 and 2003, 15.3% had a CD4 cell count below 50
cells/mm3 (8). In a Spanish prospective cohort of antiretroviral-
naive HIV-1-infected individuals, 18% had reached the AIDS
stage and 32% had a CD4 cell count of 200 cells/mm3 at enroll-
ment (16). Initial entry to medical care in the later stages of HIV
disease is mainly due to late testing, particularly in populations
with poor access to health care services, such as communities of
color, young adults, immigrants, or poor city dwellers (17–19). In
a cross-sectional study conducted in North Carolina among pa-
tients who initiated HIV care for the first time, Dennis et al. re-
ported that more than 40% of patients presented with a CD4 cell
count of 200/mm3 or an AIDS-defining event (18). In a study at
the Veterans Health Administration, more than half of the HIV-
infected patients presented with AIDS (19). In France, several
studies have shown the same types of results. Among the 1,077
patients enrolled in the ANRS-EN12-VESPA survey, a represen-
tative sample of the French HIV-infected population, one-third of
patients were classified as late testers, presenting with either clin-
ical AIDS events or CD4 counts of 200/mm3 at diagnosis (20).
The overall prevalence of delayed access to care (CD4 cell count
of 200/mm3 or an AIDS-defining event) was 35.7% in the
French Hospital Database on HIV (ANRS CO4 FHDH) (21).
Mortality and morbidity remain high in these late testers, de-
spite cART. Indeed, in the FHDH, the mortality hazard ratio in
patients with delayed access to care was 13.9 in the first 6 months
and remained significantly higher than 1 during the subsequent 4
years, despite initiation of cART (21). Thus, improving therapeu-
tic efficacy is needed, and it is appropriate to evaluate combina-
tions of more than three drugs to initiate treatment in this popu-
lation of patients.
Few randomized studies have compared a four-antiretroviral-
drug combination to standard cART. In three studies of PI-con-
taining cART (22–24), no beneficial effect was observed in the
four-drug arm, but the PI regimen was probably not optimal (nel-
finavir or unboosted indinavir). In the ACTG A5095 study, a com-
bination of three NRTIs plus efavirenz was not more effective in
reducing the plasma HIV load or increasing the CD4 cell count
than two NRTIs plus efavirenz (25). However, patients were not
severely immunosuppressed in this trial, (i.e., baseline CD4 cell
count, 240 cells/mm3). In the present study, we chose enfuvirtide
for several reasons. First, when the trial was designed, enfuvirtide
was the only approved entry inhibitor and it seemed that it would
be interesting to evaluate a combination including a drug inter-
acting with targets other than reverse transcriptase or protease.
Second, enfuvirtide appeared to be appropriate for patients with a
poor clinical condition, considering its excellent systemic safety
profile, the lack of drug interactions, and its parenteral adminis-
tration, preventing a high pill burden in this context of four-drug
therapy.
TABLE 3 AIDS events in the ANRS 130 Apollo trial
AIDS event
No. of events (no. of new AIDS events)
Enfuvirtide
group
Control
group Total
Total 31 (19) 17 (11) 48 (30)
Mycobacterial infection 7 (6) 4 (3) 11 (9)
Esophageal candidiasis 4 (3) 4 (2) 8 (5)
Cytomegalovirus infection 5 (3) 2 (2) 7 (5)
Kaposi’s sarcoma 5 (1) 1 (1) 6 (2)
Recurrent pneumonia 2 (1) 1 (1) 3 (2)
Cryptosporidiosis 2 (2) 2 (2)
Cryptococcus infection 2 (1) 2 (1)
Pneumocystis pneumonia 1 (1) 1 2 (1)
Toxoplasmosis 2 2
HIV encephalitis 2 (1) 2 (1)
Progressive multifocal
leukoencephalitis
1 (1) 1 (1)
Lymphoma 1 (1) 1 (1)
Salmonella septicemia 1 1
TABLE 4 Laboratory abnormalities in the ANRS 130 Apollo trial
Laboratory
abnormality
No. (%) of patients
Enfuvirtide group
(n  100)
Control group
(n  94) Total (n  194)
Any grade 92 (92) 87 (93) 179 (92)
Grade 2 58 (58) 57 (61) 115 (59)
Grade 3 or 4 19 (19) 22 (23) 41 (21)
TABLE 5 Grade 3 and 4 laboratory abnormalities in the ANRS 130
Apollo trial
Grade 3 or 4 abnormality
No. of events
Enfuvirtide
group
(n  28)
Control
group
(n  29)
Total
(n  57)
Leukopenia/neutropenia (2,000/750
cells/mm3)
13 13 26
ASAT, ALAT, PAL, bilirubin 5
ULNa
11 4 15
Related to antiretroviral drugs 1 1
Triglycerides (8.6 mmol/liter) 1 3 4
Related to lopinavir 1 1
Related to lopinavir and
emtricitabine-tenofovir
1 1
Phosphatemia (1.4 mg/dl) 1 3 4
Related to emtricitabine-tenofovir 1 2 3
Platelets (50,000 cells/mm3) 1 2 3
Hemoglobin (7 g/dl) 1 1 2
Proteinuria 2 2
Related to emtricitabine-tenofovir 1 1
a ASAT, aspartate transaminase; ALAT, alanine transaminase; PAL, alkaline
phosphatase.
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The Apollo trial is the first randomized comparative clinical
trial evaluating the effect of intensification of standard cART with
enfuvirtide in naive HIV-1-infected patients with advanced dis-
ease. This strategy trial did not show a difference between the two
arms in the proportion of patients with a CD4 cell count of 200/
mm3 after 6 months of therapy. There was no trend of a better
CD4 response in the intensified arm whatever the category of CD4
level at baseline (50, 50 to 100, and 100/mm3). Our results
differ from those of the pilot study reported by Bonora et al. (26),
in which addition of enfuvirtide to cART at the initial phase of
treatment resulted in an improved CD4 cell count. However, the
latter study had two major limitations: the small sample size (11
patients per arm) and the observational nature of the comparison.
In our study, although intensification of backbone cART did not
result in immunological benefit, it induced a more rapid decline in
plasma HIV-1 RNA levels, and the proportion of patients with
HIV-1 loads below 50 copies/ml was significantly higher in the
enfuvirtide arm. However, the more rapid decline of HIV-1 RNA
at week 24 in the enfuvirtide arm did not translate into an im-
proved CD4 cell count response or improved antiviral efficacy
after week 48. The improved antiviral activity in the intensified
arm suggests that the lack of an enhanced CD4 response did not
result from impaired adherence to treatment. A virological sub-
study reporting resistance and viral tropism data did not show any
difference in viral resistance at baseline. There was a trend for a
more frequent switch from CCR5 to CXCR4 in the enfuvirtide
arm; whether this could participate in the lack of an immunolog-
ical benefit with enfuvirtide remains to be discussed (27). There
was no difference between arms in terms of new AIDS-defining
events and/or death. The rate of clinical progression was similar to
data from other studies performed in such a population (12, 28),
and our findings reflect the spectrum of opportunistic infections
reported in resource-rich countries. As reported in the ACTG
A5164 trial (12), the most frequent opportunistic infections oc-
curring as new AIDS-defining events under therapy were myco-
bacterial infections (nine events), esophageal candidiasis (five
events), and cytomegalovirus infections (five events).
Interruption of the strategy occurred mainly in the intensifica-
tion arm, with 15 patients stopping enfuvirtide mostly due to poor
convenience or local discomfort. However, in spite of advanced
HIV disease and constraints related to twice-daily subcutaneous
administration, enfuvirtide appeared to be well accepted. As it
could be anticipated by toxicity data available from previous stud-
ies, the incidence of grade 3 or 4 laboratory abnormalities
was similar in both arms, confirming the biological safety of
enfuvirtide.
The proportion of patients with IRIS was 18%. This is consis-
tent with the incidence of IRIS in similar cohorts, in which 17 to
25% of patients initiating cART develop manifestations of the
syndrome (29–31). As reported in other studies, IRIS cases were
most often dermatological or associated with mycobacterial infec-
tions. As expected, considering the CD4 cell count pattern over
time, IRIS cases were not more frequent in the intensification arm,
in spite of an improved early virological response.
The trial was powered to detect differences in an immunolog-
ical surrogate marker of AIDS progression and survival, and our
primary endpoint was based on the CD4 cell count response at 6
months. Several studies have shown that the impact of cART is
primarily seen on morbidity and mortality events in the first 6
months of therapy (10–12), suggesting that early improvement in
immune responsiveness is critical to prevent clinical progression.
In a retrospective analysis in urban Zambia, a CD4 cell count
increase of less than 100/mm3 at 6 months was associated with an
increased risk of death after 6 months (13). Our primary endpoint
was analyzed at the time point that, furthermore, matched with
the end of enfuvirtide administration.
The backbone cART was a combination of tenofovir-emtricitabine
with boosted lopinavir or efavirenz and was in agreement with the
recommendations current at the time that the trial was conducted.
In fact, boosted darunavir or atazanavir was not yet recommended
as first-line therapy during this period. It has to be stressed that
80% of patients received boosted PI therapy; in this clinical set-
ting, physicians tended to prefer the boosted PI-based antiretro-
viral regimen, probably because of its stronger genetic barrier,
thus avoiding the selection of resistant viral strains that could
affect potential choices for further lines of therapy (32).
In conclusion, intensification of standard cART through the
addition of enfuvirtide in naive HIV-1-infected patients with ad-
vanced disease did not improve the CD4 cell count response to
treatment up to 48 weeks, although it induced a faster virological
response. These results suggest that this therapeutic strategy
would not decrease the risk of clinical progression following ini-
tiation of treatment in these subjects. However, intensification of
cART merits further investigation with compounds from other
classes, such as integrase inhibitors or CCR5 inhibitors.
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